Awardee OrganizationUNIVERSITY OF CONNECTICUT SCH OF MED/DNT
Description
Abstract Text
DESCRIPTION (provided by applicant): C/EBP transcription factors are known to stimulate adipocyte differentiation, and mounting evidence suggests that
osteoblasts and adipocytes share a common pluripotent progenitor in the bone
marrow. We prepared transgenic mice with Col1a1 promoter-targeted expression of
FLAG-tagged p20C/EBPbeta in an effort to enhance osteoblast differentiation at
the expense of adipogenesis. Surprisingly, however, we found that all four
lines of transgenic pOBCol3.6-FLp20C/EBPbeta mice exhibit osteopenia.
Preliminary histological evidence suggests that low bone mass may be due to
impaired osteoblast differentiation or function. We hypothesize that mice with
targeted expression of p20C/EBPbeta have osteopenia resulting from decreased
bone formation, and that p20C/EBPbeta inhibits osteoblast differentiation in
vivo. In Specific Aim 1, we will characterize the bone phenotype of transgenic mice using microcomputed tomography, static and dynamic
histomorphometry, and measurement of transgene expression by Northern blotting
and immunohistochemistry. C/EBP gene knock-out mice will be screened for the
presence of a similar phenotype. In Specific Aim 2, we will determine the
effects of p20C/EBPbeta expression on osteoblast differentiation and function
using ex vivo bone marrow stromal and primary calvarial cell culture models. Cell proliferation will be determined in primary calvarial cultures by cell
number and by (3H)thymidine incorporation. Osteoblast differentiation will be
assessed in both models by the formation of mineralized bone nodules and the
expression of osteoblast markers such as Col1a1, bone sialoprotein and
osteocalcin. As a first step toward understanding the mechanism of p20C/EBPbeta
action, its dimerization partners in primary osteoblastic cells will be
identified by immunoprecipitation and electrophoretic mobility shift analysis.
The proposed studies should help to elucidate role of transcription factors,
specifically members of the C/EBP family, in the control of osteoblast
differentiation and bone mass.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
022254226
UEI
H6D6JMXJXDE6
Project Start Date
15-September-1992
Project End Date
31-August-2006
Budget Start Date
01-September-2002
Budget End Date
31-August-2003
Project Funding Information for 2002
Total Funding
$326,250
Direct Costs
$225,000
Indirect Costs
$101,250
Year
Funding IC
FY Total Cost by IC
2002
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$326,250
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AR040668-09
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AR040668-09
Patents
No Patents information available for 5R01AR040668-09
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AR040668-09
Clinical Studies
No Clinical Studies information available for 5R01AR040668-09
News and More
Related News Releases
No news release information available for 5R01AR040668-09
History
No Historical information available for 5R01AR040668-09
Similar Projects
No Similar Projects information available for 5R01AR040668-09